Advertisement
UK markets close in 7 hours 35 minutes
  • FTSE 100

    8,073.22
    +28.41 (+0.35%)
     
  • FTSE 250

    19,796.62
    -3.10 (-0.02%)
     
  • AIM

    756.13
    +1.26 (+0.17%)
     
  • GBP/EUR

    1.1630
    +0.0002 (+0.02%)
     
  • GBP/USD

    1.2432
    -0.0020 (-0.16%)
     
  • Bitcoin GBP

    53,614.61
    +329.65 (+0.62%)
     
  • CMC Crypto 200

    1,418.29
    -5.81 (-0.41%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.37
    +0.01 (+0.01%)
     
  • GOLD FUTURES

    2,334.20
    -7.90 (-0.34%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,165.47
    +336.54 (+2.00%)
     
  • DAX

    18,194.12
    +56.47 (+0.31%)
     
  • CAC 40

    8,099.84
    -5.94 (-0.07%)
     

What Analysts Recommend for CBAY and VKTX

What Analysts Recommend for CBAY and VKTX

This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.